Melanotan 2 Research Guide: A Cyclic Peptide and Its Receptor Story
Explore the cyclic peptide behind Hero MT-2, its melanocortin research background, key identity distinctions, and the documentation needed for laboratory work.
Quick facts
| Catalog name | MT-2 Melanotan 2 |
|---|---|
| Common literature name | Melanotan-II, MT-II |
| Structure class | Cyclic heptapeptide analog of alpha-MSH |
| Exported size | 10 mg |
| Research distinction | Different from Melanotan I and bremelanotide |
| Hero product | MT-2 Melanotan 2 |
Melanotan 2, also called Melanotan-II or MT-II, is a cyclic peptide investigated in melanocortin research. Its ring structure is part of its scientific identity. It is not simply a second size or strength of Melanotan 1, and the number in the name is not a potency ranking.
Hero’s export lists MT-2 Melanotan 2 as a 10 mg research product. This guide explains the structural background, the kinds of experiments that shaped the literature, and the distinction between a named research compound and a characterized sample used in an assay.
MT-2 Melanotan 2. View catalog product
Origin story: changing the shape of a hormone analog
Early melanotropin research explored how peptide structure influenced biological activity. A 1989 paper examined cyclic lactam analogs of alpha-melanotropin using molecular-design approaches. This research provides context for the development of MT-II and related compounds (Al-Obeidi et al., 1989).
A cyclic peptide contains a structural connection that constrains part of its chain. That can change the shapes available to the molecule, but cyclic is not a universal claim about selectivity, stability, or biological performance. Those properties still need measurement.
For a literature search, use Melanotan-II as well as Melanotan 2. Retain the exact compound name when taking notes. An article discussing the broader melanocortin family may include several materials with different structures and target profiles.
How Melanotan 2 research works
Melanocortin research involves a family of receptors rather than a single interchangeable target. A useful experiment identifies the receptor subtype, expression system, concentration range, and readout. The family name alone does not establish which receptor produced a measured response.
A receptor-binding measurement asks how a compound interacts with a target under stated conditions. A functional measurement asks what signal follows. Both can be informative, but a binding result should not be renamed as a complete biological effect.
A preformulation study characterized MT-II as a cyclic heptapeptide and examined physicochemical measurements including ionization and partitioning. Those measurements address formulation questions rather than a general claim about outcomes in people (Lan et al., 1994).
The Melanotan 1 guide covers a distinct analog. Comparing their structures helps explain why similar names should not lead to shared molecular specifications or borrowed results.
Key studies: design, chemistry, and evidence scope
| Source | Research setting | Contribution | Boundary |
|---|---|---|---|
| Al-Obeidi et al., 1989 | Peptide design and experimental characterization | Cyclic melanotropin analog research | Not a result for every melanocortin ligand |
| Lan et al., 1994 | Physicochemical and preformulation work | Material properties relevant to formulation questions | Not a universal solvent or shelf-life instruction |
| Lot characterization | The actual supplied material | Identity and reported analytical properties | Not a clinical or receptor-function study |
These evidence layers should stay separate in a research summary. A measured physicochemical property helps describe the molecule under the tested conditions. It does not identify the contents of an unrelated vial or establish the response that vial will produce.
Historical paper titles can also describe a proposed development aim. That wording should not be copied as an established indication. The actual methods and results determine what the study supports.
When comparing experiments, record which material was tested, its stated chemical form, and the model. Then record what was measured. This makes disagreements easier to interpret and prevents a familiar compound name from hiding incompatible methods.
Weak spots: a research history is not an authorization
FDA’s safety-risk information identifies concerns for Melanotan II, including impurity and immunogenicity questions and serious events described in case reports. A case report can identify a concern without establishing a population-wide event rate or proving causality for every reported association (FDA, 2026).
As of November 17, 2026, this guide does not establish an approved clinical use for Hero MT-2. It does not provide personal tanning instructions, an administration schedule, or a claim that a research material provides protection from sunlight.
Exact identity remains essential. Ring structure, terminal chemistry, and chemical form should match the requirements of the experiment. A mass-compatible signal alone does not establish every structural or functional property.
The PT-141 guide covers another related research name. Its evidence belongs to that compound and the specified preparations, rather than supplying validation for MT-II.
Handling Melanotan 2 in the lab
The exported 10 mg format describes nominal material mass. Select preparation conditions using the actual lot documentation and the validated requirements of the assay. Do not derive solvent compatibility solely from a generic peptide-storage description.
For arithmetic only, nominal 10 mg at a final solution volume of 2 mL gives 5 mg/mL. At a final volume of 4 mL, it gives 2.5 mg/mL. Use a suitable laboratory vessel; these hypothetical final volumes do not establish vial capacity.
These calculations do not supply a functional test concentration or a stability interval. If the experiment requires molarity, use the molecular-weight basis appropriate to the documented material, including relevant form and counterion information.
The calculator supports mass-per-volume arithmetic. The half-life explainer helps distinguish biological exposure from solution stability, and the COA guide explains the analytical record.
Keep the catalog product ID, lot number, material specification, preparation date, solvent, and dilution history together. An analytical result should be assigned only to the lot it describes. Retain any unresolved identity or testing questions before interpreting a new biological result.
Melanotan 2 FAQ
Is Melanotan 2 the same as Melanotan 1?
No. They are distinct analogs. Similar names do not establish identical structures, receptor profiles, or preparation requirements.
What does cyclic heptapeptide mean?
It describes a seven-residue peptide with a cyclic structural connection. It is a structural classification, not a guarantee of a particular biological effect.
Does the 10 mg label specify a solution concentration?
No. Concentration also requires a final solution volume. Nominal vial mass alone cannot supply it.
What is Hero MT-2?
It is the MT-2 Melanotan 2 entry in Hero’s supplied catalog, listed with a 10 mg variant. The export does not independently confirm current live stock or a lot’s analytical results.
MT-2 Melanotan 2. View catalog product
References
- Al-Obeidi F, et al. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-2561. Source.
- Lan EL, et al. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. 1994;83(8):1081-1084. Source.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Checked November 17, 2026. Source.
